Evidence map›Paper›PMID 36853128›Full record

Observational studyThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2023

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB.

C Zeng, C D Mitnick, C Hewison, M Bastard, P Khan, K J Seung, M L Rich, S Atwood, N Melikyan, N Morchiladze and 17 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  8. Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

C ZengDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
C D MitnickDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA, Partners In Health (PIH), Boston, MA, USA, Division of Global Health Equity, Brigham and Women´s Hospital, Boston, MA, USA.
C HewisonMedical Department, Médecins Sans Frontières (MSF), Paris, France.
M BastardField Epidemiology Department, Epicentre, Paris, France.
P KhanInteractive Research and Development Global, Singapore, Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
K J SeungPartners In Health (PIH), Boston, MA, USA, Division of Global Health Equity, Brigham and Women´s Hospital, Boston, MA, USA.
M L RichPartners In Health (PIH), Boston, MA, USA, Division of Global Health Equity, Brigham and Women´s Hospital, Boston, MA, USA.
S AtwoodDivision of Global Health Equity, Brigham and Women´s Hospital, Boston, MA, USA.
N MelikyanField Epidemiology Department, Epicentre, Paris, France.
N MorchiladzeMSF, Sokhumi, Georgia.
N KhachatryanMSF, Yerevan, Armenia.
M KhmyzMSF, Minsk, Belarus.
C G RestrepoMSF, Yangon, Myanmar.
N SalahuddinIndus Hospital & Health Network (IHHN), Karachi, Pakistan.
E KazmiCenter for Disease Control and Prevention, Directorate General Health Services, Sindh, Pakistan.
A A DahriCenter for Disease Control and Prevention, Directorate General Health Services, Sindh, Pakistan.
S AhmedInteractive Research and Development, Karachi, Pakistan.
F VaraineMedical Department, Médecins Sans Frontières (MSF), Paris, France.
S C VilbrunHaitian Group for the Study of Kaposi´s Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.
L OyewusiPIH, Maseru, Lesotho.
A GelinZanmi Lasante, Port-au-Prince, Haiti.
K TintayaPIH/Socios En Salud Sucursal Peru, Lima, Peru.
L T YeraliyevaNational Scientific Center of Phthisiopulmonology of the Ministry of Health of the Republic of Kazakhstan, Kazakhstan.
S HamidBishoftu General Hospital, Bishoftu, Ethiopia.
U KhanInteractive Research and Development Global, Singapore.
H HuergaField Epidemiology Department, Epicentre, Paris, France.
M F FrankeDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.

Funding

STRUCTURAL ANALYSIS OF HIV1 ENVELOPE GLYCOPROTEINSR01AI040895 · NIAID · DANA-FARBER CANCER INSTITUTE · PI SODROSKI, JOSEPH G · 1997 to 2006
$3.9M
Strengthening evidence on optimal multidrug-resistant tuberculosis treatment regimens through improved epidemiologic methodsR01AI146095 · NIAID · HARVARD MEDICAL SCHOOL · PI FRANKE, MOLLY FORREST · 2020 to 2024
$3.6M
NIAID NIH HHS R01 AI040895NIAID NIH HHS R01 AI146095
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AlgorithmsTuberculosis, Multidrug-ResistantHumansRifampinRifampin

Identifiers

PMID36853128
PMCPMC9879081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.